New York, New York (PRWEB) December 15, 2013
A new Lipitor lawsuit (http://www.lipitorlawsuitcenter.com/) filed in Kentucky claims that a woman’s Type 2 diabetes could have been avoided were it not for allegedly inadequate warnings provided by Pfizer, Inc., Bernstein Liebhard LLP reports. The complaint, which was filed in U.S. District Court, Western District of Kentucky, alleges that the Plaintiff’s use of Lipitor for nearly four years resulted in her diabetes diagnosis. The lawsuit further alleges that Pfizer marketed Lipitor as safe and effective for years, despite its knowledge of data tying Lipitor to elevated blood glucose levels and the development of Type 2 diabetes. (Case No. 3:13 v-01178-TBR)
“We are investigating a number of cases involving Lipitor patients who report similar experiences to the plaintiffs, and will be monitoring this and other Lipitor lawsuits filed in courts around the country with great interest,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to alleged victims of Lipitor and diabetes.
Lipitor Diabetes Allegations
According to the Kentucky filing, Pfizer did not add warnings to the drug’s label regarding the association between Lipitor and diabetes until February 2012, after the U.S. Food & Drug Administration mandated that it do so. The lawsuit further claims that the current label remains inadequate and still fails to warn consumers about the serious risk of Type 2 diabetes associated with the medication.
In October, a petition was filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) which revealed that more than 100 Lipitor lawsuits involving diabetes allegations had been filed in courts around the country. The petition seeks the consolidation of all federally-filed Lipitor lawsuits in a multidistrict litigation, and transfer of the cases to a single judge in U.S. District Court, District of South Carolina. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))
According to court documents, this is the second time plaintiffs in Lipitor lawsuits have requested a multidistrict litigation. A petition filed in April was rejected by the JPML on the grounds that there were too few filings to warrant a consolidated proceeding. However, at that time, just around a dozen Lipitor lawsuits had been filed in federal courts. The JPML has not yet schedule a hearing on this most recent petition.
Alleged victims of Lipitor and diabetes may be eligible for compensation for medical bills, lost wages, pain and suffering and more. Learn more about Lipitor lawsuits at Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com